COMMETS- Combination MCI Metabolic Syndrome
NCT06072963 on ClinicalTrials.gov · last registry update 2026-07-27
Recruiting now, toward 80 participants. Due to report 1 December 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Cognitive change - The effect of the combination of Semaglutide and intranasal insulin on cognitive functioning. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 30 January 2024 — 2 years so far. semaglutide is approved in the US, but not for metabolic syndrome and neurodegenerative — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Rutgers, The State University of New Jersey
- Sponsor type
- Other
- Enrollment
- 80
- Started
- 2024-01-30
- Primary completion
- 2027-12-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Cognitive change - The effect of the combination of Semaglutide and intranasal insulin on cognitive functioning.
Conditions studied
Alzheimer Disease · Mild Cognitive Impairment · Metabolic Syndrome
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.